FDA Approves Low-dose Regimen Of Premarin Vaginal Cream To Treat Moderate To Severe Postmenopausal Dyspareunia Painful Sexual Intercourse PREMARIN® (conjugated estrogens) Vaginal Cream 0.5 g has been approved by the U.S. Food and Drug Administration (FDA) for a new indication and a new less frequent twice-weekly dosing regimen to treat moderate to severe postmenopausal dyspareunia (painful sexual intercourse) announced Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE).
Source: www.medicalnewstoday.comRasilez®, First-in-class Direct Renin Inhibitor, Provides Greater Reduction In High Blood Pressure Than ACE Inhibitor Ramipril New clinical data presented show first-in-class direct renin inhibitor Rasilez® (aliskiren), known as Tekturna® in the US, provides significantly greater blood pressure reductions in patients with high blood pressure aged 65 and over, compared to the angiotensin-converting enzyme (ACE) inhibitor ramipril[1].
Source: www.medicalnewstoday.comOramed Pharmaceuticals Presents Results Of Oral Administration Of Exenatide-4; Proof Of Concept Pharmacodynamic Study In Dogs Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of proprietary drug delivery systems, presented the results of its exploratory study entitled "Enteral Administration of Exenatide-4; Proof of Concept Pharmacodynamic Study in Dogs" at the Diabetes Technology Society's Conference in Bethesda, Maryland.
Source: www.medicalnewstoday.comThromboGenics Announces Promising Six Month Follow-Up Results From Its Phase IIb Trial Of Microplasmin (MIVI III) For Treatment Of Visual Disorders ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on eye disease, vascular disease and cancer, announces promising six month follow-up results from its Phase IIb MIVI III trial, which was designed to evaluate the safety and efficacy of microplasmin in vitrectomy. The results were presented at the American Academy of Ophthalmology in Atlanta, USA, by Dr.
Source: www.medicalnewstoday.com
# posted by Network @ 9:00 AM
